key: cord-0699339-srt21qzt
authors: Giménez, Estela; Alberola, Juan; Torres, Ignacio; Albert, Eliseo; Alcaraz, María Jesús; Botija, Pilar; Amat, Paula; Remigia, María José; Beltrán, María José; Rodado, Celia; Huntley, Dixie; Olea, Beatriz; Navarro, David
title: Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty® COVID-19 vaccine
date: 2021-11-02
journal: J Infect
DOI: 10.1016/j.jinf.2021.10.026
sha: fea75ec349805d4d1bd5e15b0ad10e8a927803ec
doc_id: 699339
cord_uid: srt21qzt

nan

We read with interest the studies published by Tré-Hardy and colleagues [1, 2] in the Journal of Infection showing a marked and significant decrease in serum SARS-CoV-2-Spike(S) antibody levels in healthcare workers at 3 and 6 months after complete vaccination with the mRNA-1273 vaccine (Spikevax). Real-world experience has shown mRNA COVID-19 vaccines to be effective in reducing incidence of both asymptomatic and symptomatic SARS-CoV-2 infections and related deaths in nursing home residents [3] , congruent with their ability to elicit robust virus-specific T and B cell immune responses in this population group [4, 5] . Nevertheless, maintaining seemingly protective immune responses in these individuals over time may be compromised by the concurrence of older age, frailty and co-morbidities. To shed light on this issue, here we assessed SARS-CoV-2-Spike (S)-targeted antibody and functional T cell responses at around 6 months after vaccination with Comirnaty® (Pfizer-BioNTech) in a previously recruited cohort [4] .

Out of 53 nursing home residents enrolled in a previous study [4] with data on B and T cell immunity at a median of 17.5 days (range, 1435 days) after second vaccine dose (baseline sample), 46 (44 females; median age, 89 years; range, 60100; Supplementary The likelihood of having detectable SARS-CoV-2 IFN-γ CD8 + and CD4 + T at follow-up was higher (P=0.03 and P=0.5) in SARS-CoV-2 recovered (8/10 and 7/10, respectively) than in naïve residents (9/36 and 25/36, respectively). For those with detectable 5 responses at both time points, overall, SARS-CoV-2-S IFN-γ CD8 + T cell frequencies decreased significantly (P=0.001) over time whereas the opposite (P=0.01) was seen for CD4 + T cells ( Figure 2C) . Interestingly, the resident lacking anti-RBD antibodies at follow-up had detectable SARS-CoV-2-S CD4 + T cell responses. In this regard, collectively, the above data suggested that SARS-CoV-2-S IFN-γ CD4 + T cells may develop later than CD8 + T cells in nursing home residents.

Supplementary Table 2 shows the combined results for all immunological parameters.

No correlation, as evaluated by the Spearman rank test, was found between anti-RBD antibody levels and SARS-CoV-2-S IFN-γ CD4 + (Rho=-0.015; P=0.94) and CD8 + (Rho:-0.18; P=0.87) T cells.

Limitations of the current study are the relatively small sample size and lack of a control group; regarding the latter, most of the 17 controls included in our previous study [4] were unfortunately not available for follow-up sampling. Secondly, neutralization assays were not carried out. In summary, our data revealed that a large percentage of nursing home residents displayed detectable SARS-CoV-2-S-reactive antibodies and T cell responses, respectively, by around 6 months after complete vaccination with Comirnaty® COVID-19 vaccine, although these generally declined over time. Whether these mid-term immune responses suffice to prevent COVID-19 remains to be determined. Our data also suggested that a booster (third) dose, which has been proposed for elderly people [9] may be delayed beyond 6 months in fully vaccinated COVID-19 recovered residents.

We are grateful to all personnel who work at nursing home residences affiliated to the 

This work received no public or private funds.

The authors declare no conflicts of interest. 

Waning antibodies in SARS-CoV-2 naïve vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers

Six-month interim analysis of ongoing immunogenicity surveillance of the mRNA-1273 7

vaccine in healthcare workers: A third dose is expected

Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents

B and T cell immune responses elicited by the Comirnaty COVID-19 vaccine in nursing-home residents

Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study

Quantitative measurement of anti-SARS-CoV-2 antibodies: Analytical and clinical evaluation

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection

Considerations in boosting COVID-19 vaccine immune responses

Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody

Figure 2. SARS-CoV-2-S-reactive IFN-γ-producing T cell levels in SARS-CoV-2

naïve and or recovered nursing home residents measured at baseline (median, 17.5 days) and follow-up (median, 195 days) after complete Comirnaty® COVID-19 vaccination

Samples mock-stimulated with phosphate-buffered saline (PBS)/dimethyl sulfoxide and costimulatory antibodies were run in parallel. Brefeldin A (10 μg/ml) was added for the last 4 h of incubation. Blood was then lysed (BD FACS lysing solution) and frozen at −80°C until tested. On the day of testing, stimulated blood was thawed at 37°C, washed, permeabilized (BD permeabilizing solution) and stained with a combination of labeled mAbs (anti-IFNγ-FITC, anti-CD4-PE, anti-CD8-PerCP-Cy5.5, and anti-CD3-APC) for 1 h at room temperature. Appropriate positive (phytohemagglutinin) and isotype controls were used. Cells were then washed

All data were corrected for background IFN-γ production (FITC-labelled isotype control antibody) and expressed as a percentage of total CD8 + or CD4 + T cells

S-reactive IFN-γ CD4 + T cells. (C) Frequencies of SARS-CoV-2-S-reactive IFN-γ

CD8 + and CD4+ T cells in nursing home residents with detectable responses at both baseline and follow-up. T cells. P-values for comparisons are shown (ns